003090

Daewoong is a holding company that provides investment and management services to a group of subsidiaries operating in the pharmaceutical and healthcare sectors. Its main subsidiaries include Daewoong Pharmaceutical, which manufactures and sells prescription drugs, over-the-counter medicines, and botulinum toxin products such as Naveva, Ulsan, and Pexclou; Daewoong Bio, which produces active pharmaceutical ingredients and finished drugs; and HanAll Biopharma, which focuses on the development of synthetic and biopharmaceuticals for autoimmune, ophthalmic, and neurological diseases. The group also engages in digital healthcare through products like the thynC smart bed monitoring system and continuous glucose monitors. Daewoong Pharmaceutical was established in 2002 following a spin-off from Daewoong, while HanAll Biopharma was founded in 1973. The company serves domestic and global markets, with significant export activity in botulinum toxin products, and maintains partnerships with entities such as Evolus and Immunovant for the commercialization and development of its therapies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage daewoong.com
Sector Healthcare IR page daewoong.com/ko
Tags
botulinum toxin, prescription drugs, active pharmaceutical ingredients, biopharmaceuticals, digital healthcare, autoimmune diseases, ophthalmology, neurology, holding company, Daewoong Pharmaceutical, Daewoong Bio, HanAll Biopharma, Naveva, Ulsan, Pexclou, Enblo, thynC, Freestyle Libre, Mobicare, CartBee, Whisky, Biotop, Eligard, Norimics, Hairgro, Verciforin, DWP216, DWP220, Batoquelimab, Immerofurbat, Tanfanercept, HL192, Evolus, Immunovant, Harbour BioMed, NurrOn Pharmaceuticals, PT Selatox Bio Pharma, PT Daewoong Group Indonesia, Daewoong Development, Daewoong Therapeutics, Apicell Therapeutics, IN Therapeutics, Daewoong Pet, Sunmaeul, Daewoong Management Development Institute, Daewoong Engineering, IDS&Trust, Danaa Data
Press page daewoong.com/ko/newsroom/news

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 16.1%
ROI 14.9%
ROIC 20.8%
Profit margin 8.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 19.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 54.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 2.068T 1.937T — 1.697T — — — — — — — — —
Net profit 175.063B 57.886B 152.665B 102.566B 78.73B 98.379B 62.439B 29.863B 66.251B 19.831B 38.623B 23.811B 40.772B
Free cash flow -37.218B -100.204B 24.211B 81.068B 64.94B 113.741B 98.555B -20.288B 73.188B — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 189B 186B 196B 227B 175B 193B 229B 223B 269B 267B
↳ YoY growth +18.2% -1.3% +5.4% +15.9% -22.9% +9.9% +18.7% -2.5% +20.7% -0.6%
↳ 5y CAGR +10.3% +11.2% +1.9% +0.4% +4.2% +2.6% +3.4% +8.8%
Borrowings, current (KRW) 124B 95.7B 207B 99.3B 147B 256B 234B 380B 0.00 209B
Borrowings, non-current (KRW) — — 200M 0.00 92.6B 94.5B 119B 65B 325B 551B
Bonds payable (KRW) 99.9B 89.9B 200B 89.9B 89.9B 200B 89.8B 89.9B 194B 334B
Lease liabilities (KRW) — — 0.00 3.61B 3.47B 5.24B 1.41B 3.91B 4.08B 3.3B
Cash and deposits (KRW) 106B 135B 95.1B 67.5B 197B 125B 190B 162B 192B 256B
Intangible assets (KRW) 159B 180B 155B 173B 186B 232B 275B 308B 356B 380B
Right-of-use assets (KRW) — — 0.00 5.46B 4.72B 5.65B 3.74B 4.34B 20.6B 18.9B
Net debt (borrowings + leases - cash) (KRW) 17.7B -39.4B 112B 35.5B 46.2B 231B 164B 287B 137B 507B
Cash flow detail
Operating cash flow (KRW) 18.8B 148B 45.4B 139B 145B 133B 149B 206B 162B 258B
Purchases of property, plant and equipment (KRW) -149B -74.6B -65.7B -40B -31.6B -68.2B -68B -181B -263B -295B
Purchases of intangible assets (KRW) -25.1B -28.5B -1.41B -28.4B -33.5B -47.3B -49.6B -47.5B -73.7B -53.2B
Dividends paid (cash effect) (KRW) -8.18B -7.68B -7.68B -7.68B -7.64B -7.48B -8.91B -8.12B -8.19B -12.6B
Share buybacks (cash effect) (KRW) — — -1.41M -3.32M -20.1B — -127M -10B 0.00 0.00
Interest paid (cash effect) (KRW) -8.01B -10.1B -10.1B -10.4B -10.7B -9.93B -11.6B -17.4B -23.7B -24.9B
Income taxes paid (cash effect) (KRW) -37.2B -4.67B -16.1B -39.2B -20.7B -43B -36.3B -37.5B -64B -42.7B
Free cash flow (OCF - PPE - intangibles) (KRW) -155B 44.7B -21.7B 70.1B 80.3B 17.7B 31.5B -23.3B -174B -90.4B
Income detail
Total comprehensive income (KRW) 31.6B 81.7B 36B 77.2B 135B 53.4B 132B 186B 69.2B 242B
Comprehensive income to owners (KRW) 18.1B 64.4B 31.2B 64.7B 98.9B 66.2B 104B 137B 65.6B 181B
Reported Apr 2, 2018 Apr 2, 2018 Mar 18, 2021 Mar 18, 2021 Mar 18, 2021 Mar 20, 2024 Aug 14, 2025 Mar 20, 2024 Aug 14, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Routine
불성실공시법인지정예고 Bull 0 Bear 4 Distress

Prompts

DAEWOONG (ticker 003090), listed in South Korea.

ETFs Holding DAEWOONG

ETF Weight in ETF Shares Market value As of
AVEE 0.02% 2,406 $ 28.555K Nov 16, 2026
AVES 0.01% 8,210 $ 97.438K Nov 16, 2026
DFSE 0.01% 2,711 $ 33.377K Nov 12, 2026
DEXC 0.01% 1,143 $ 14.072K Nov 12, 2026
DFEM 0.00% 34,309 $ 422.4K Nov 12, 2026
DFEV 0.00% 6,309 $ 77.674K Nov 12, 2026
DFAX 0.00% 17,983 $ 221.4K Nov 12, 2026
DFAE 0.00% 6,638 $ 81.725K Nov 12, 2026
AVEM 0.00% 47,422 $ 562.814K Nov 16, 2026
AVSE 0.00% 334 $ 3,963.98 Nov 16, 2026
AVXC 0.00% 648 $ 7,690.59 Nov 16, 2026